Illumina s Q3 Net Losses Widen but Still Beat Forecasts | GenomeWeb

NEW YORK, Oct 12 – Illumina reported Thursday third-quarter net losses of $3.9 million, or 15 cents a share, on a pro forma basis, compared with a net loss of $1.5 million, or 11 cents a share in the year ago period.

Consensus estimates forecast net losses of 20 cents a share, based on two analysts surveyed by First Call/Thomson Financial.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.